EktomunĀ®'s unique format translates into a number of clinical and production advantages. It can potently trigger instant tumor cell destruction as well as long-term immune responses and can be manufactured in comparatively small facilities using a straight-forward process.

undefinedLearn more about the TriomabĀ® advantages

 

GD2 is a clinically validated tumor target opening many potential applications for ektomunĀ®. It is broadly present in tumors of neuroectodermal origin, including small cell lung cancer (SCLC), melanoma, neuroblastoma and glioblastoma. In healthy tissues, however, GD2 expression is strictly limited to very few, distinct cell types.